Concise summaries of everything published in the latest weekly issue of the New England Journal of Medicine (NEJM). NEJM publishes new medical research findings, review articles, and editorial opinion on topics of importance to biomedical science and clinical practice.
…
continue reading
Player FM - Internet Radio Done Right
23 subscribers
Checked 4h ago
Added nine years ago
Content provided by Oncology Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Similar to Oncology Times - OncTimes Talk
Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
As She Rises brings together local poets and activists from throughout North America to depict the effects of climate change on their home and their people. Each episode carries the listener to a new place through a collection of voices, local recordings and soundscapes. Stories span from the Louisiana Bayou, to the tundras of Alaska to the drying bed of the Colorado River. Centering the voices of native women and women of color, As She Rises personalizes the elusive magnitude of climate cha ...
…
continue reading
Android Backstage, a podcast by and for Android developers. Hosted by developers from the Android engineering team, this show covers topics of interest to Android programmers, with in-depth discussions and interviews with engineers on the Android team at Google. Subscribe to Android Developers YouTube → https://goo.gle/AndroidDevs
…
continue reading
Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
The day's biggest news dissected by the day's newsmakers. Diverse opinions from across the political spectrum. The show that makes you decide, are you the Left, Right or the Centre?
…
continue reading
How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
A live podcast show, that’s like a morning radio show, just much better. Live from 6h00-8h00 Monday, Wednesday and Friday. Clever, funny, outrageous and sometimes very silly. Come for the guests, stay for the laughter. Also check out our other shows on The Real Network for more entertainment.
…
continue reading
FEEL FREE TO LISTEN TO THIS PODCAST IN ANY ORDER! Order up! We're here to serve up a refreshing glass of The Halo-Halo Show with a scoop of the scoop - Trending topics all around the world. A dash of lighthearted fun, a splash of silly insights, and a spoonful of laughter! Topped with our answers to the burning questions you've sent over to our Leche Flan mail! Hosted by Radio DJ's/Hosts/All-Around Weirdos Rica Garcia and JC Tevez - Bringing you a wonderful mix (*wink wink*) of a good time! ...
…
continue reading
Where the biggest names in the world of sport go one-on-one with sports journalist Mark Howard. From ultimate highs to tear-jerking lows, Howie lifts the lid on the real stories behind the headlines. He sits down with the biggest names in Australian & world sport, finding out how they started out, what makes them tick, how they deal with the big wins and the big losses, and how they take on sport and life from here.
…
continue reading
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
))
Novel Score Selects Patients With Intermediate Risk Prostate Cancer Safe for Active Surveillance
Manage episode 469528618 series 1021077
Content provided by Oncology Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance.
A research study using APP4 was reported at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. First author Ruben Del Castillo, MD, a radiation oncologist from the Sunnybrook Health Sciences Centre in Toronto, Canada, shared the details.
193 episodes
ShareManage episode 469528618 series 1021077
Content provided by Oncology Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance.
A research study using APP4 was reported at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. First author Ruben Del Castillo, MD, a radiation oncologist from the Sunnybrook Health Sciences Centre in Toronto, Canada, shared the details.
193 episodes
All episodes
×
1 Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities at High Risk 12:53
12:53 
Play Later 
Play Later 
Lists 
Like 
Liked12:53
Play Later Play Later Lists Like LikedMasood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients. Moghul told the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco how the study addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.…
1 Striking Microbiome Bacterial Population Differences Distinguish Metastatic Prostate Cancer From Non-Metastatic Disease 8:40
8:40 Play Later Play Later Lists Like Liked8:40
Play Later Play Later Lists Like LikedAt the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key microbial species in the gut microbiomes of patients with metastatic prostate cancer that distinguished them from those with non-metastatic disease. This was in the PROMISE-JAPAN study with 869 Japanese patients. After talking about his group’s new data, lead researcher Koji Hatano, MD, a urologist from Osaka University in Japan, discussed the insights this has given doctors into the metastatic process and potential ways of modifying it.…
1 Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer 9:41
9:41 Play Later Play Later Lists Like Liked9:41
Play Later Play Later Lists Like LikedNo description available
1 Novel Score Selects Patients With Intermediate Risk Prostate Cancer Safe for Active Surveillance 10:08
10:08 Play Later Play Later Lists Like Liked10:08
Play Later Play Later Lists Like LikedA numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance. A research study using APP4 was reported at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. First author Ruben Del Castillo, MD, a radiation oncologist from the Sunnybrook Health Sciences Centre in Toronto, Canada, shared the details.…
1 Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities 12:53
12:53 Play Later Play Later Lists Like Liked12:53
Play Later Play Later Lists Like LikedMasood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed his group’s findings from the Man Van study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients conducted in Greater London. Moghul told the 2025 ASCO Genitourinary Cancers Symposium in San Francisco how the study had addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.…
1 Episode 3, Better Informed Patient Journeys 12:27
12:27 Play Later Play Later Lists Like Liked12:27
Play Later Play Later Lists Like LikedIn the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. David O’Malley, and Bobbie R, an ovarian cancer patient. Dr. O’Malley will highlight how HRD testing empowers ovarian cancer patients to make more informed decisions with their doctors to help guide their treatment journey, and Bobbie will provide insight into her experience with HRD testing. Dr. David O’Malley is a professor in the department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James. Bobbie is a stage 3C ovarian cancer patient who lives in Rochester, New York. Bobbie is an animal rights activist, vegetarian, and exerciser who recently retired from the healthcare field, having worked as a registered nurse and owner of a healthcare staffing firm. Following her diagnosis in July of 2021, Bobbie participated in biomarker testing which indicated that she was breast cancer gene (BRCA) negative and homologous recombination deficiency (HRD) positive. After undergoing surgery and chemotherapy as first-line treatment, Bobbie’s oncologist explained that she was eligible for a poly-ADP ribose polymerase (PARP) inhibitor due to her HRD status and on March 7, 2022, Bobbie started on a PARP inhibitor for maintenance treatment. As she continues treatment in 2024, Bobbie celebrates over 45 years of marriage with her husband and looks forward to traveling the United States, reading good books, and spending time with her dogs. For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com. This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokespeople's opinions and experiences.…
In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients. Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in Syracuse, NY, Dr. Crane completed her residency at the University of Virginia and a fellowship at The University of Texas MD Anderson Cancer Center in Gynecologic Oncology. She is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology and Obstetrics and Gynecology. Dr. Crane is a Clinical Associate Professor of Obstetrics and Gynecology at the Wake Forest University School of Medicine. For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com . This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokesperson's opinions and experience.…
1 Episode 1, A Precision Medicine Approach for Advanced Ovarian Cancer 16:40
16:40 Play Later Play Later Lists Like Liked16:40
Play Later Play Later Lists Like LikedIn the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches. Dr. Kathleen Moore is a Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Associate Director of Clinical Research and Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. A graduate of the University of Washington School of Medicine, WA, Dr. Moore completed her residency in gynecology at the University Health Center of Pittsburgh in Pittsburgh, PA and completed a fellowship in gynecologic oncology at the University of Oklahoma College of Medicine in Oklahoma City, OK. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care. For more information, visit: https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com . This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokeperson's opinions and experience.…
1 KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma 7:33
7:33 Play Later Play Later Lists Like Liked7:33
Play Later Play Later Lists Like LikedThe pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable advanced or metastatic melanoma. Results from the study were reported at the European Society for Medical Oncology (ESMO) 2024 Annual Congress, held in Barcelona, Spain.…
1 Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified 16:09
16:09 Play Later Play Later Lists Like Liked16:09
Play Later Play Later Lists Like LikedAlthough one in five colorectal cancers having microsatellite instability and expressing the Werner Helicase (WRN) gene could be treated with drugs that inhibit WRN, the effectiveness of such an approach has been limited by resistance. However, researchers identified the Cys727 mutation as being solely responsible for WRN inhibitor resistance. This potentially opens the door to using WRN inhibitors in the cancer clinic by inactivating this resistance gene. At the EORTC-NCI-AACR 2024 Molecular Targets and Cancer Therapeutics Symposium Gabriele Picco, PhD, Senior Staff Scientist in the Translational Cancer Genomics Team at the Wellcome Sanger Institute’s Genome Campus, reported findings about WRN resistance mechanisms that may clear the path to introducing WRN inhibitors to the cancer clinic to fight microsatellite unstable cancers.…
1 Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development 9:21
9:21 Play Later Play Later Lists Like Liked9:21
Play Later Play Later Lists Like LikedA tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location. The ESMO Tumour-Agnostic Classifier and Screener was the result of work by a multidisciplinary team of international experts led by the ESMO Precision Medicine Working Group. At the conference, Benedikt Westphalen, MD, a medical oncologist and molecular biologist who is Head of the Precision Oncology Program at the University of Munich in Germany, talked about the details with Oncology Times correspondent Peter Goodwin.…
1 Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma 7:25
7:25 Play Later Play Later Lists Like Liked7:25
Play Later Play Later Lists Like LikedFindings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching early to immune checkpoint inhibition appeared to bring better rates of overall survival than saving immunotherapy for use as salvage treatment later on. The ESMO 2024 Annual Congress heard from the randomized Phase II ImmunoCobiVem trial that a switch to immunotherapy after only 3 months treatment with drugs targeted to the mutation gave equivalent or better survival than continuing with targeted therapy.…
1 Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified 7:33
7:33 Play Later Play Later Lists Like Liked7:33
Play Later Play Later Lists Like LikedThe pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable advanced or metastatic melanoma. Results from the study were reported at the European Society for Medical Oncology (ESMO) 2024 Annual Congress, held in Barcelona, Spain.…
1 Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer 6:59
6:59 Play Later Play Later Lists Like Liked6:59
Play Later Play Later Lists Like LikedA clinically meaningful benefit in overall survival was found in the second interim analysis of the randomized, double-blind, Phase III KEYNOTE-A18 study of immunotherapy together with concurrent chemoradiotherapy among 1,060 patients who had newly diagnosed, previously untreated high-risk locally advanced cervical cancer. A multinational team of researchers, led from Italy, reported findings at the ESMO Congress 2024. There was a statistically significant increase in 36-month overall survival in patients treated with pembrolizumab, in addition to chemoradiotherapy, in comparison to those in the control group who received standard chemoradiation alone.…
1 The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front 13:54
13:54 Play Later Play Later Lists Like Liked13:54
Play Later Play Later Lists Like LikedIn this podcast episode, Ruchika Talwar, MD, sits down with Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences and Clinical Professor of Pathology at University of California, San Francisco, to discuss the importance of ultra-comprehensive genomic profiling in advanced cancer therapy selection. The two talk about the OncoExTra® test from Exact Sciences, which includes whole-exome DNA sequencing and whole-transcriptome RNA sequencing, and how the latest updates to industry guidelines will continue to influence approaches to cancer care.…
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.
Similar to Oncology Times - OncTimes Talk
Concise summaries of everything published in the latest weekly issue of the New England Journal of Medicine (NEJM). NEJM publishes new medical research findings, review articles, and editorial opinion on topics of importance to biomedical science and clinical practice.
…
continue reading
Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
As She Rises brings together local poets and activists from throughout North America to depict the effects of climate change on their home and their people. Each episode carries the listener to a new place through a collection of voices, local recordings and soundscapes. Stories span from the Louisiana Bayou, to the tundras of Alaska to the drying bed of the Colorado River. Centering the voices of native women and women of color, As She Rises personalizes the elusive magnitude of climate cha ...
…
continue reading
Android Backstage, a podcast by and for Android developers. Hosted by developers from the Android engineering team, this show covers topics of interest to Android programmers, with in-depth discussions and interviews with engineers on the Android team at Google. Subscribe to Android Developers YouTube → https://goo.gle/AndroidDevs
…
continue reading
Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
The day's biggest news dissected by the day's newsmakers. Diverse opinions from across the political spectrum. The show that makes you decide, are you the Left, Right or the Centre?
…
continue reading
How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
A live podcast show, that’s like a morning radio show, just much better. Live from 6h00-8h00 Monday, Wednesday and Friday. Clever, funny, outrageous and sometimes very silly. Come for the guests, stay for the laughter. Also check out our other shows on The Real Network for more entertainment.
…
continue reading
FEEL FREE TO LISTEN TO THIS PODCAST IN ANY ORDER! Order up! We're here to serve up a refreshing glass of The Halo-Halo Show with a scoop of the scoop - Trending topics all around the world. A dash of lighthearted fun, a splash of silly insights, and a spoonful of laughter! Topped with our answers to the burning questions you've sent over to our Leche Flan mail! Hosted by Radio DJ's/Hosts/All-Around Weirdos Rica Garcia and JC Tevez - Bringing you a wonderful mix (*wink wink*) of a good time! ...
…
continue reading
Where the biggest names in the world of sport go one-on-one with sports journalist Mark Howard. From ultimate highs to tear-jerking lows, Howie lifts the lid on the real stories behind the headlines. He sits down with the biggest names in Australian & world sport, finding out how they started out, what makes them tick, how they deal with the big wins and the big losses, and how they take on sport and life from here.
…
continue reading
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
